WARSAW, Poland--(BUSINESS WIRE)--JJP Biologics, a private biopharmaceutical company developing innovative antibody-based therapies, announces a positive decision, issued by the European Medicines ...
Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the program Supports the feasibility of intravenous and subcutaneous dosing regimens in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results